| This week's sponsor is Premier Research. | |  | Overcoming Risk in Oncology Drug Development
Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. Built for biotech. |
Today's Rundown Featured Story | | | Tuesday, June 11, 2019 A cystic fibrosis drug has been approved for use in the U.K. since 2016 but is still being denied to patients over its cost. Now, the question over who is really responsible for its costly creation has arisen. |
|
|
Top Stories Tuesday, June 11, 2019 Genmab and Johnson & Johnson have teamed up to develop a successor to their multiple myeloma blockbuster Darzalex. The deal gives J&J the option to license the asset after clinical proof of concept for $150 million plus milestones and royalties. Tuesday, June 11, 2019 ReViral has named Alex Sapir as CEO. Sapir arrives at the midphase respiratory syncytial virus specialist six months after abruptly leaving Dova Pharmaceuticals. Monday, June 10, 2019 Read the case study to learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Tuesday, June 11, 2019 One year after setting up shop, immuno-oncology startup Oncologie has bagged another $80 million that will bankroll three clinical-stage programs, licensing deals and the development of the company’s biomarker platform. Tuesday, June 11, 2019 Thomas Schinecker, global business head of the division’s burgeoning centralized and point-of-care solutions, will take over as CEO of Roche Diagnostics starting Aug. 1. | This week's sponsor is Cobra Biologics. | |  |
Cobra provides expert scale up and manufacturing of customers’ live biotherapeutic microbiota products, manufacturing to cGMP standards for clinical and commercial scale. We also offer DNA and viral vector services, with experienced project teams nurturing customers’ products within GMP approved facilities. Visit our website to find out more. |
Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. | 
